Orion Oyj (OTCMKTS:ORINY) Short Interest Update

Orion Oyj (OTCMKTS:ORINY - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 600 shares, an increase of 200.0% from the May 15th total of 200 shares. Approximately 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 400 shares, the short-interest ratio is currently 1.5 days.

Orion Oyj Stock Down 0.7%

Shares of ORINY stock traded down $0.27 on Friday, hitting $36.18. The stock had a trading volume of 221 shares, compared to its average volume of 2,106. The business has a 50 day moving average of $31.29 and a 200 day moving average of $27.92. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of 28.71 and a beta of 0.07. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. Orion Oyj has a 12-month low of $21.10 and a 12-month high of $36.45.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $0.23 EPS for the quarter. The company had revenue of $373.03 million during the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, analysts expect that Orion Oyj will post 1.18 EPS for the current year.

Orion Oyj Increases Dividend

The business also recently declared a dividend, which was paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th were paid a dividend of $0.4478 per share. The ex-dividend date of this dividend was Monday, April 7th. This is a positive change from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is presently 24.43%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.